Growth Factor News and Research

RSS

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

Study reveals why colorectal cancer still returns in some patients after treatment

Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.

17 Nov 2015

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.

17 Nov 2015

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).

15 Nov 2015

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

15 Nov 2015

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

14 Nov 2015

New findings reveal association between colorectal cancer and melanoma drug treatment

Veteran cancer reseacher Prof. Emeritus Alexander Levitzki of Hebrew University of Jerusalem says new findings show link between colorectal cancer and melanoma drug treatment knoqwn as "NT157" in two recently published studies in journal, "Ocogene."

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

New treatment may help patients with chronic renovascular disease

A new treatment may help patients with a chronic kidney condition that can also lead to heart problems and premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

6 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Higher insulin levels linked to worse prognosis in advanced breast cancer

Patients with breast cancer that has spread to other parts of the body (metastasised) and who have higher insulin levels than normal, but are not diabetic, have a significantly worse prognosis compared with those with normal insulin levels, a researcher will tell the Advanced Breast Cancer Third International Consensus Conference tomorrow (Friday).

5 Nov 2015

TUM researchers uncover signaling pathways that play vital role in self-renewal of blood stem cells

Stem cells have two important capabilities: they can develop into a wide range of cell types and simultaneously renew themselves, creating fresh stem cells. Using a model of the blood forming (hematopoietic) system, researchers at the Technical University of Munich have now been able to precisely determine, which signaling pathways play an essential role in the self-renewal of blood stem cells.

4 Nov 2015

Blood stem cell self-renewal dependent on surroundings

Stem cells have two important capabilities: they can develop into a wide range of cell types and simultaneously renew themselves, creating fresh stem cells. Using a model of the blood forming (hematopoietic) system, researchers at the Technical University of Munich (TUM) have now been able to precisely determine, which signaling pathways play an essential role in the self-renewal of blood stem cells. A particularly decisive role in this process is the interactive communication with surrounding tissue cells in the bone marrow.

3 Nov 2015

Good news for patients suffering from dry age-related macular degeneration

Scientists have good news for patients who suffer from currently untreatable dry age-related macular degeneration (dry AMD). In a new study, researchers identified a potential target for future therapies to slow the progression of the blinding condition. Published in Investigative Ophthalmology & Visual Science, the findings indicate that treatments currently used for other conditions could also work for dry AMD.

3 Nov 2015

Growth Factor News and Research

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Study reveals why colorectal cancer still returns in some patients after treatment

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

New findings reveal association between colorectal cancer and melanoma drug treatment

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

AACR rapid and dramatic responses in TRK fusion patients

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

New tool could help identify patients most likely to benefit from chemoprevention

New treatment may help patients with chronic renovascular disease

Hutchison MediPharma begins sulfatinib Phase I trial in US

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

Higher insulin levels linked to worse prognosis in advanced breast cancer

TUM researchers uncover signaling pathways that play vital role in self-renewal of blood stem cells

Blood stem cell self-renewal dependent on surroundings

Good news for patients suffering from dry age-related macular degeneration

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News